Candriam S.C.A. Invests $12.53 Million in Illumina, Inc. $ILMN

Candriam S.C.A. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) in the 1st quarter, HoldingsChannel.com reports. The firm acquired 101,680 shares of the life sciences company’s stock, valued at approximately $12,533,000.

A number of other institutional investors have also made changes to their positions in the company. Invesco Ltd. raised its holdings in shares of Illumina by 97.0% during the fourth quarter. Invesco Ltd. now owns 2,747,986 shares of the life sciences company’s stock worth $360,426,000 after purchasing an additional 1,352,731 shares during the period. AQR Capital Management LLC boosted its position in shares of Illumina by 30.3% during the fourth quarter. AQR Capital Management LLC now owns 4,426,126 shares of the life sciences company’s stock worth $580,531,000 after buying an additional 1,028,099 shares during the period. Morgan Stanley boosted its position in Illumina by 66.0% during the 4th quarter. Morgan Stanley now owns 2,529,045 shares of the life sciences company’s stock worth $331,710,000 after acquiring an additional 1,005,474 shares during the period. Nordea Investment Management AB grew its position in Illumina by 2,792.2% in the 4th quarter. Nordea Investment Management AB now owns 944,500 shares of the life sciences company’s stock valued at $124,145,000 after buying an additional 911,843 shares in the last quarter. Finally, Vaughan Nelson Investment Management L.P. bought a new position in shares of Illumina in the first quarter valued at approximately $106,462,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Price Performance

Illumina stock opened at $190.20 on Monday. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.75 and a quick ratio of 1.36. Illumina, Inc. has a fifty-two week low of $88.00 and a fifty-two week high of $196.66. The firm has a fifty day moving average price of $161.31 and a two-hundred day moving average price of $141.52. The firm has a market cap of $28.78 billion, a price-to-earnings ratio of 34.58, a P/E/G ratio of 3.56 and a beta of 1.47.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.05 by $0.10. The company had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm’s revenue was up 4.8% compared to the same quarter last year. During the same period last year, the business posted $0.97 earnings per share. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. As a group, analysts forecast that Illumina, Inc. will post 5.21 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Keith A. Meister sold 235,000 shares of the stock in a transaction on Monday, June 1st. The stock was sold at an average price of $163.63, for a total transaction of $38,453,050.00. Following the sale, the director owned 2,830,452 shares in the company, valued at approximately $463,146,860.76. This represents a 7.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the company’s stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total value of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares in the company, valued at $2,093,386.24. This trade represents a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 1,003,769 shares of company stock worth $155,710,908. Insiders own 2.90% of the company’s stock.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina is being highlighted by market commentary as a biotech and life sciences momentum name, with analysts pointing to stronger earnings trends and sector leadership in healthcare. Zacks Investment Ideas feature highlights: XLV, XBI, LLY, EXEL, PTCT, FTRE and ILMN
• Positive Sentiment: Several articles frame ILMN as a strong momentum stock and note that it has outperformed recently, reinforcing bullish trading interest. Illumina (ILMN) Is Up 6.87% in One Week: What You Should Know
• Positive Sentiment: Illumina announced new executive appointments, naming Michael Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, which may be viewed as a move to strengthen commercial execution and governance. Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer
• Positive Sentiment: Illumina also announced it will report second-quarter 2026 results on July 30, keeping attention on upcoming fundamentals and guidance. Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
• Neutral Sentiment: Coverage also repeated bullish valuation and “mooning stock” themes, but these were largely commentary pieces rather than new company-specific developments. Illumina Stock Gains 43.7% in 2026: What’s Powering the Rally?
• Negative Sentiment: Short-interest data showed no meaningful bearish positioning change, so it does not currently add fresh downside pressure, though the report itself was unusual and offered little real signal. Illumina (ILMN) Stock May Be 27% Undervalued Following Strong Q1 Results

Wall Street Analyst Weigh In

Several brokerages recently weighed in on ILMN. Piper Sandler raised their target price on Illumina from $170.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 1st. Canaccord Genuity Group reduced their target price on Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Guggenheim increased their price target on shares of Illumina from $180.00 to $200.00 and gave the stock a “buy” rating in a research report on Monday, June 29th. Barclays lifted their price objective on Illumina from $122.00 to $145.00 and gave the company an “underweight” rating in a research report on Wednesday, June 24th. Finally, Evercore reiterated an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, Illumina currently has an average rating of “Hold” and a consensus price target of $150.44.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.